Moreover, in the Myc-CaP syngeneic PCa model, combining JQ1 treatment with anti-CTLA-4 immunotherapy resulted in an additive effect, leading to an increased CD8/Treg ratio, which is beneficial for antitumor immune responses 199. This evidence concerns the gene MYC and posterior cortical atrophy.